Abstract:Nanobodies, also known as VHHs, originate from the serum of Camelidae. Nanobodies have considerable advantages over conventional antibodies, including smaller size, more modifiable, and deeper tissue penetration, making them promising tools for immunotherapy and antibody-drug development. A high-throughput nanobody screening platform is critical to the rapid development of nanobodies. To date, droplet-based microfluidic systems have exhibited improved performance compared to the traditional phage display technology in terms of time and throughput. In realistic situations, however, it is difficult to directly apply the technology to the screening of nanobodies. Requirements of plasma cell enrichment and high cell viability, as well as a lack of related commercial reagents, are leading causes for impeding the development of novel methods. We overcame these obstacles by constructing a eukaryotic display system that secretes nanobodies utilizing homologous recombination and eukaryotic transformation technologies, and the significant advantages are that it is independent of primary cell viability and it does not require plasma cell enrichment in advance. Next, a signal capture system of "SA-beads + Biotin-antigen + nanobody-6 × His + fluorescence-labeled anti-6 × His (secondary antibody)" was designed for precise localization of the eukaryotic-expressed nanobodies in a droplet. Based on this innovation, we screened 293T cells expressing anti-PD-L1 nanobodies with a high positive rate of targeted cells (up to 99.8%). Then, single-cell transcriptomic profiling uncovered the intercellular heterogeneity and BCR sequence of target cells at a single-cell level. The complete complementarity determining region (CDR3) structure was obtained, which was totally consistent with the BCR reference. This study expanded the linkage between microfluidic technology and nanobody applications and also showed potential to accelerate the rapid transformation of nanobodies in the large-scale market.

Peptidisc-assisted hydrophobic clustering towards the production of multimeric and multispecific nanobody proteins

Plug-and-play nucleic acid-mediated multimerization of biparatopic nanobodies for molecular imaging

Gluebodies improve crystal reliability and diversity through transferable nanobody mutations that introduce constitutive close contacts

Megabodies expand the nanobody toolkit for protein structure determination by single-particle cryo-EM

Enzymatic Protein Immobilization for Nanobody Array

A new generation of nanobody research tools using improved mass spectrometry-based discovery methods

Structure-based Engineering of Anti-Gfp Nanobody Tandems As Ultra-High-affinity Reagents for Purification

Modular design of bi- and multi-specific knob domain fusions

Structural insights into two distinct nanobodies recognizing the same epitope of green fluorescent protein

A computationally guided approach to improve expression of VHH binders

Design of Nanobody-based Bispecific Constructs by in silico Affinity Maturation and Umbrella Sampling Simulations

Tandem nanobody: A feasible way to improve the capacity of affinity chromatography

Enhancing Nanobody Immunoassays through Ferritin Fusion: Construction of a Salmonella-Specific Fenobody for Improved Avidity and Sensitivity

Supramolecular Heterodimer Peptides Assembly for Nanoparticles Functionalization

Bispecific Engineered Antibody Domains (nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn.

Designed proteins assemble antibodies into modular nanocages

Nanobody in a Double "Y"-Shaped Assembly: A Promising Candidate for Lateral Flow Immunoassays

Engineered Protein-G variants for plug-and-play applications

Display of Polyvalent Hybrid Antibodies on the Cell Surface for Enhanced Cell Recognition

Generation and Screening of Antigen-Specific Nanobodies from Mammalian Cells Expressing the BCR Repertoire Library Using Droplet-Based Microfluidics

Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the CH1-Cλ interface